Regenxbio (RGNX) Research & Development (2014 - 2025)

Regenxbio's Research & Development history runs 12 years deep, the most recent figure standing at $59.6 million for Q4 2025.

• In Q4 2025, Research & Development rose 18.32% year-over-year to $59.6 million; the TTM figure through Dec 2025 stood at $228.3 million (up 9.48% YoY), while the FY2025 annual figure was $228.3 million, up 9.48% from the prior year.
• Research & Development was $59.6 million for Q4 2025 at Regenxbio, up from $56.1 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $63.3 million in Q3 2022 to a low of $39.7 million in Q1 2021.
• Historically, Research & Development has averaged $54.6 million across 5 years, with a median of $55.7 million in 2022.
• The sharpest annual moves came in 2022 and 2024: Research & Development soared 40.04% in 2022, then dropped 18.4% in 2024.
• A 5-year view of Research & Development shows it stood at $48.0 million in 2021, then surged by 30.28% to $62.5 million in 2022, then decreased by 10.92% to $55.7 million in 2023, then dropped by 9.52% to $50.4 million in 2024, then advanced by 18.32% to $59.6 million in 2025.
• The last three Research & Development figures came in at $59.6 million (Q4 2025), $56.1 million (Q3 2025), and $59.5 million (Q2 2025), per Business Quant data.